Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

MedImmune and Advaxis study immuno-oncology combination treatment; MedImmune could get future rights

Executive Summary

AstraZeneca PLC’s MedImmune LLC and cancer immunotherapies company Advaxis Inc. will work together to research a new combination therapy consisting of MedImmune’s MEDI4736 and Advaxis’ ADXSHPV aimed at preventing and treating HPV-associated cervical cancer and squamous cell carcinoma of the head and neck.

Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Vaccines
  • Biotechnology
    • Immuno-Oncology
    • Large Molecule
      • Antibodies
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)
    • Trial Collaborations

Related Companies